Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000387574

Medchemexpress LLC Purvalanol A | 212844-53-6 | 98.61% | 388.89 | 1 ML
SDP

Catalog No. 5000387574
Encompass_Preferred

Purvalanol A is a potent CDK inhibitor. It inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, and 75 nM, respectively. It also inhibits cdc28 (S. cerevisiae) and erk1 with IC50s of 80 and 9000 nM. Purvalanol A shows inhibitory activities against the NCI panel of 60 human tumor cell lines, with an average GI50 of 2 μM. It is a 2.5-fold more potent inhibitor of CDK2, and potently inhibits DYRK1A and other protein kinases in the low micromolar range. It selectively inhibits the phosphorylation of cellular proteins and prevents the increases of cyclins D and E during serum-induced G1 phase progression.

  • Potent CDK inhibitor
  • Inhibits various cyclin-dependent kinases (CDKs)
  • Exhibits cytotoxic effects on various cancer cell lines
  • Selectively inhibits the phosphorylation of cellular proteins
  • Prevents increases of cyclins D and E during G1 phase progression

Catalog No. 50-003-87574 Supplier Medchemexpress LLC Supplier No. HY18299A10MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Purvalanol A is a potent CDK inhibitor. It inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, and 75 nM, respectively. It also inhibits cdc28 (S. cerevisiae) and erk1 with IC50s of 80 and 9000 nM. Purvalanol A shows inhibitory activities against the NCI panel of 60 human tumor cell lines, with an average GI50 of 2 μM. It is a 2.5-fold more potent inhibitor of CDK2, and potently inhibits DYRK1A and other protein kinases in the low micromolar range. It selectively inhibits the phosphorylation of cellular proteins and prevents the increases of cyclins D and E during serum-induced G1 phase progression.

  • Potent CDK inhibitor
  • Inhibits various cyclin-dependent kinases (CDKs)
  • Exhibits cytotoxic effects on various cancer cell lines
  • Selectively inhibits the phosphorylation of cellular proteins
  • Prevents increases of cyclins D and E during G1 phase progression

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.